Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications

BMC Neuroscience

Volumn 12, Issue , 2011, Pages

  Briones, Teresita L ^a   Woods, Julie ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; HISTONE DEACETYLASE; METHOTREXATE; ANTINEOPLASTIC AGENT; HISTONE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COGNITIVE DEFECT; CONTROLLED STUDY; DISCRIMINATION LEARNING; DRUG DOSE REGIMEN; DRUG EFFICACY; ENZYME ACTIVITY; EUTHANASIA; FATIGUE; FEMALE; HIPPOCAMPUS; HISTONE ACETYLATION; HISTONE MODIFICATION; LEARNING; LONG TERM MEMORY; MAZE TEST; MEMORY; NONHUMAN; PHYSICAL ACTIVITY; RAT; WEIGHT REDUCTION; ACETYLATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; HISTONE DEACETYLASES; HISTONES; NEUROGENESIS; NEURONAL PLASTICITY; RATS; RATS, WISTAR;

EID: 84855384100     PISSN: None     EISSN: 14712202     Source Type: Journal    
DOI: 10.1186/1471-2202-12-124     Document Type: Article

References (29)

1. Schagen SB, vD FS, Muller MJ, Boorgerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999, 85:640-650. 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G, 10091737.
2. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998, 90:210-218. 10.1093/jnci/90.3.210, 9462678.
3. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995, 4:61-66.
4. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER, et al. Neuropsychologic impact of standard dose chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002, 20:485-493. 10.1200/JCO.20.2.485, 11786578.
5. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003, 21:4175-4183. 10.1200/JCO.2003.01.119, 14615445.
6. Brezden CB, Phillips KA, Abdolell M. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000, 18:2695-2701.
7. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003, 9:967-982.
8. Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Theil E, Zander AR, Schulz-Kindermann F, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supoorted high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 2006, 17:415-423. 10.1093/annonc/mdj108, 16357023.
9. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early stage breast carcinoma. Cancer 2005, 104:2499-2507. 10.1002/cncr.21482, 2653200, 16247788.
10. Sieklucka-Dziuba M, Saczonek J, Dziuba J, Kleinrok Z. Central action of some cytostatics-methotrexate (MTX) and doxorubicin (DXR). II. The influence on the seizure activity and the learning and memory processes in mice. Ann Univ Mariae Curie Sklodowska [Med] 1998, 53:81-88.
11. Phillips PC, Thaler HT, Berger CA, Fleisher M, Wellner D, Allen JC, Rottenberg DA. Acute high-dose methothrexate neurotoxicity in the rat. Ann Neurol 1986, 20:583-589. 10.1002/ana.410200505, 3789673.
12. Mustafa S, Awalker A, Bennett G, Wigmore PM. 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurosci 2008, 28:323-330. 10.1111/j.1460-9568.2008.06325.x, 18702703.
13. Seigers R, Schagen SB, Beerling W, Boogerd W, van Tellingen O, van Dam FS, Koolhaas JM, Buwalda B. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methothrexate in the rat. Behav Brain Res 2008, 186:168-175. 10.1016/j.bbr.2007.08.004, 17854921.
14. Macleod JE, Deleo JA, Hickey WF, Ahles TA, Saykin AJ, Bucci DJ. Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 2007, 181:168-172. 10.1016/j.bbr.2007.04.003, 17509697.
15. Reiriz AB, Reolon GK, Pressler T, Rosado JO, Henriques JAP, RR, Schwartsmann G. Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 2006, 12:5000-5001. 10.1158/1078-0432.CCR-06-0138, 16914590.
16. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006, 85:66-75. 10.1016/j.pbb.2006.07.010, 16935324.
17. Lee GD, Longo DL, Wang T, Rifkind JM, Abdul-Raman L, Mamczarz JA, Duffy KB, Spangler EL, Taub DD, Mattson MP, et al. Transient improvement in cognitive function and synaptic plasticity in rats following cancer chemotherapy. Clin Cancer Res 2006, 12:198-205. 10.1158/1078-0432.CCR-05-1286, 16397043.
18. Levine MN, Whelan T. Adjuvant chemotherapy for breast cancer - 30 years later. NEJM 2006, 355:1920-1922. 10.1056/NEJMe068204, 17079767.
19. Barrett RM, Wood MA. Beyond transcription factors: the role of chromatin modifying enzymes in regulating transcription required for memory. Learn mem 2008, 15:460-467. 10.1101/lm.917508, 18583646.
20. Hsieh J, Nakashima K, Kuwabara T, Meija E, Gage FH. Histone deacetylase inhibition-mediated neuronal differentiation of multiptent adult neural progenitor cells. Proc Natl Acad Sci 2004, 101:16659-16664. 10.1073/pnas.0407643101, 527137, 15537713.
21. Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat Rev Neurosci 2010, 11:33-350.
22. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006, 5:22.21-22.23.
23. Janelsins MC, Roscoe JA, Berg MJ, Thompson BD, Gallagher MJ, Morrow GR, Heckler CE, Jean-Pierre P, Opanashuk LA, Gross RA. IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Invest 2010, 28:544-553. 10.3109/07357900903405942, 3024545, 20014946.
24. Levenson JM, Sweatt JD. Epigenetic mechanisms in memory formation. Nat Rev Neurosci 2005, 6:108-118. 10.1038/nrn1604, 15654323.
25. Kim HJ, Rosenfeld MG. Epigenetic control of stem cell fate to neurons and glia. Arch Pharm Res 2010, 33:1467-1473. 10.1007/s12272-010-1001-z, 21052927.
26. Huang WY, Yang PM, Chang YF, Marquez VE, Chen CC. Methothrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol 2011, 81:510-517. 10.1016/j.bcp.2010.11.014, 21114963.
27. Farnebo M, Bykov VJ, Wilman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun 2010, 396:85-89. 10.1016/j.bbrc.2010.02.152, 20494116.
28. Kuhn H, Dickinson-Anson H, Gage FH. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 1996, 17:5820-5829.
29. Briones TL, Rogozinska M, Woods J. Environmental experience modulates ischemia-induced amyloidogenesis and enhances functional recovery. J Neurotrauma 2009, 24:613-625.